» Articles » PMID: 7490328

A "quickscore" Method for Immunohistochemical Semiquantitation: Validation for Oestrogen Receptor in Breast Carcinomas

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1995 Sep 1
PMID 7490328
Citations 405
Authors
Affiliations
Soon will be listed here.
Abstract

Immunohistochemistry is increasingly used in the assessment of markers for breast cancer prognosis. Semiquantitation is frequently desirable but, other than by the use of image analysis, the approaches currently in use are cumbersome. The most common method used is the H-score which takes into consideration the staining intensity in conjunction with the percentage of cells staining positively in breast carcinoma tissue. A "quickscore" has been developed which dispenses with the need to count individual cells. The quantitative biochemical Abbott enzyme immunoassay (EIA) and the Dako immunohistochemical assay (IHA) incorporating a semiquantitative H-score, have been used as standards against which the IHA quickscore for the semiquantitation of oestrogen receptor expression was tested. A good correlation was found between the quickscore and the EIA, which was as good as that between the H-score and EIA. The quickscore is a valid approach and there is no advantage in using the more rigorous H-score. A positive cut off quickscore of > or = 3 has been suggested.

Citing Articles

Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity.

Yusuf A, Amri M, Ugusman A, A Hamid A, Abd Rahman I, Mokhtar M Biomedicines. 2025; 13(2).

PMID: 40002703 PMC: 11853574. DOI: 10.3390/biomedicines13020289.


Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer.

Maeda T, Ono M, Osako T, Chiba T, Baba S, Iesato A Cancer Med. 2025; 14(4):e70666.

PMID: 39967410 PMC: 11836529. DOI: 10.1002/cam4.70666.


Epigenetic silencing of promotes laryngeal squamous cell carcinoma development by inhibiting the Hippo pathway.

Jia Y, Liu J, Shi J, Zhang C, Wang X, Zhao L Oncol Rep. 2025; 53(2.

PMID: 39749700 PMC: 11718434. DOI: 10.3892/or.2024.8861.


Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

Kouvaraki M, Zerdes I, Sifakis E, Sarafidis M, Matikas A, Tzoras E Int J Cancer. 2024; 156(8):1621-1633.

PMID: 39729390 PMC: 11826144. DOI: 10.1002/ijc.35319.


The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer.

Ablinger C, Neureiter D, Mahr T, Mayr C, Kiesslich T, Maeding N Cancer Biol Ther. 2024; 25(1):2439057.

PMID: 39668430 PMC: 11789727. DOI: 10.1080/15384047.2024.2439057.


References
1.
Andersen J, Bentzen S, Poulsen H . Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol. 1988; 24(3):377-84. DOI: 10.1016/s0277-5379(98)90006-2. View

2.
Kinsel L, Szabo E, Greene G, Konrath J, Leight G, McCarty Jr K . Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989; 49(4):1052-6. View

3.
Saccani Jotti G, Johnston S, Salter J, Detre S, Dowsett M . Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol. 1994; 47(10):900-5. PMC: 502173. DOI: 10.1136/jcp.47.10.900. View

4.
Andersen J . Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. Acta Oncol. 1992; 31(6):611-27. DOI: 10.3109/02841869209083843. View

5.
Barnes D, Dublin E, Fisher C, Levison D, Millis R . Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?. Hum Pathol. 1993; 24(5):469-76. DOI: 10.1016/0046-8177(93)90158-d. View